Rick Livesey
@ricklivesey.bsky.social
Cellular and molecular neuroscience, neurodegeneration & drug discovery. Founder and CEO of Talisman Therapeutics & Gen2 Neuroscience, honorary prof at UCL. Cambridge UK.
Nice summary of the study here on the Alzforum www.alzforum.org/news/researc...
Fragments of Tau’s Microtubule Binding Region Mess with Synapses | ALZFORUM
www.alzforum.org
March 7, 2025 at 4:17 PM
Nice summary of the study here on the Alzforum www.alzforum.org/news/researc...
So nothing definitive about AD, but consistent with role for LRRK2 in regulating tau uptake/clearance/spreading in tauopathies
November 28, 2024 at 11:23 AM
So nothing definitive about AD, but consistent with role for LRRK2 in regulating tau uptake/clearance/spreading in tauopathies
Ed Jabbari and Huw Morris at UCL carried a GWAS for rate of progression of progressive nuclear palsy (tauopathy): the primary variant identified that increases rate of progression increases LRRK2 expression pubmed.ncbi.nlm.nih.gov/33341150/
Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study - PubMed
PSP Association, CBD Solutions, Medical Research Council (UK).
pubmed.ncbi.nlm.nih.gov
November 28, 2024 at 11:23 AM
Ed Jabbari and Huw Morris at UCL carried a GWAS for rate of progression of progressive nuclear palsy (tauopathy): the primary variant identified that increases rate of progression increases LRRK2 expression pubmed.ncbi.nlm.nih.gov/33341150/
Some interesting clinical data related to this: AD-type tau pathology is present in LRRK2-PD cases (actaneurocomms.biomedcentral.com/articles/10....).
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease - Acta Neuropathologica Communications
Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson’s disease (PD). While the clinical presentation of LRRK2 mutation carriers is similar to that of idiop...
actaneurocomms.biomedcentral.com
November 28, 2024 at 11:23 AM
Some interesting clinical data related to this: AD-type tau pathology is present in LRRK2-PD cases (actaneurocomms.biomedcentral.com/articles/10....).
Punchline: might LRRK2 therapeutics in development for PD be useful in Alzheimer's and other tauopathies?
November 27, 2024 at 4:27 PM
Punchline: might LRRK2 therapeutics in development for PD be useful in Alzheimer's and other tauopathies?